Literature DB >> 19371312

Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study.

Leyla Cekici1, Arschang Valipour, Robab Kohansal, Otto Chris Burghuber.   

Abstract

AIMS: To investigate short-term effects of inhaled salbutamol on haemodynamic changes and cardiovascular autonomic control.
METHODS: A randomized, single-blinded, placebo-controlled study of 0.2 mg of inhaled salbutamol was conducted on 12 healthy nonsmoking volunteers with a mean age of 24 +/- 2 years at two different testing sessions. Non-invasively obtained continuous haemodynamic measurements of cardiac output, beat-to-beat arterial blood pressure, and total peripheral resistance were recorded prior to and for a total of 120 min after inhalation of the respective study drug. Continuous cardiovascular autonomic tone was recorded using power spectral analysis of heart rate and blood pressure variability. Spontaneous baroreceptor activity was assessed by the sequence method.
RESULTS: There were no significant changes in any of the baseline parameters between the different testing sessions. Inhalation of salbutamol caused a significant increase in cardiac output from 6.7 +/- 1.3 to 7.7 +/- 1.4 l min(-1) (P < 0.05), and a decrease in total peripheral resistance from 1076 +/- 192 to 905 +/- 172 dyne s(-1) cm(-5) (P < 0.05) within 15 min after inhalation. Moreover, salbutamol significantly increased sympathetically mediated low-frequency heart rate variability (P < 0.01), whereas parasympathetically mediated high-frequency heart rate variability decreased (P < 0.01). All changes persisted for approximately 30 min and were fully reversible at 120 min. There were no significant changes in systolic blood pressure variability or spontaneous baroreceptor activity.
CONCLUSIONS: Inhalation of therapeutic doses of salbutamol in healthy subjects resulted in significant haemodynamic changes and a shift of sympathovagal balance towards increased sympathetic tone in the absence of baroreceptor activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371312      PMCID: PMC2679102          DOI: 10.1111/j.1365-2125.2009.03377.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  50 in total

1.  Heart rate variability and spontaneous baroreflex sequences in supine healthy volunteers subjected to nasal positive airway pressure.

Authors:  Arschang Valipour; Frank Schneider; Wolfgang Kössler; Sleman Saliba; Otto Chris Burghuber
Journal:  J Appl Physiol (1985)       Date:  2005-07-07

Review 2.  Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.

Authors:  E H Walters; P G Gibson; T J Lasserson; J A E Walters
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Eur Heart J       Date:  1996-03       Impact factor: 29.983

4.  Adaptive autoregressive modeling used for single-trial EEG classification.

Authors:  A Schlögl; D Flotzinger; G Pfurtscheller
Journal:  Biomed Tech (Berl)       Date:  1997-06       Impact factor: 1.411

5.  Effects of inhaled albuterol and ipratropium bromide on autonomic control of the cardiovascular system.

Authors:  A J Dagnone; J L Parlow
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

6.  Power spectrum analysis of heart rate variability to assess the changes in sympathovagal balance during graded orthostatic tilt.

Authors:  N Montano; T G Ruscone; A Porta; F Lombardi; M Pagani; A Malliani
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

7.  Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study.

Authors:  H Tsuji; F J Venditti; E S Manders; J C Evans; M G Larson; C L Feldman; D Levy
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

8.  Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics.

Authors:  S Larsson; N Svedmyr
Journal:  Am Rev Respir Dis       Date:  1977-11

9.  Haemodynamic responses to salbutamol and isometric exercise are altered in young adults with mild asthma.

Authors:  W Stephen Waring; Rachel B Leigh
Journal:  Eur J Clin Pharmacol       Date:  2005-01-27       Impact factor: 2.953

10.  Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease.

Authors:  J Rossinen; J Partanen; B Stenius-Aarniala; M S Nieminen
Journal:  J Intern Med       Date:  1998-05       Impact factor: 8.989

View more
  15 in total

1.  Different effects of tocolytic medication on blood pressure and blood pressure amplification.

Authors:  Isabelle Fabry; Peter De Paepe; Jan Kips; Sebastian Vermeersch; Luc Van Bortel
Journal:  Eur J Clin Pharmacol       Date:  2010-11-16       Impact factor: 2.953

2.  The influence of tocolytic drugs on cardiac function, large arteries, and resistance vessels.

Authors:  Isabelle G Fabry; Peter De Paepe; Jan G Kips; Luc M Van Bortel
Journal:  Eur J Clin Pharmacol       Date:  2011-04-15       Impact factor: 2.953

3.  Pharmacology, basic & clinical: contrasts & coherence.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

4.  Safety of repeated hyperpolarized helium 3 magnetic resonance imaging in pediatric asthma patients.

Authors:  Nanae Tsuchiya; Mark L Schiebler; Michael D Evans; Robert V Cadman; Ronald L Sorkness; Robert F Lemanske; Daniel J Jackson; Nizar N Jarjour; Loren C Denlinger; Sean B Fain
Journal:  Pediatr Radiol       Date:  2020-01-24

Review 5.  β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives.

Authors:  Maria Gabriella Matera; Luigino Calzetta; Mario Cazzola
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

6.  Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD).

Authors:  Arnoldus J R van Gestel; Joerg Steier
Journal:  J Thorac Dis       Date:  2010-12       Impact factor: 2.895

Review 7.  Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.

Authors:  Mario Cazzola; Luigino Calzetta; Barbara Rinaldi; Clive Page; Giuseppe Rosano; Paola Rogliani; Maria Gabriella Matera
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

8.  A Controlled Trial of Inhaled Bronchodilators in Familial Dysautonomia.

Authors:  Bat-El Bar-Aluma; Ori Efrati; Horacio Kaufmann; Jose-Alberto Palma; Lucy Norcliffe-Kaufmann
Journal:  Lung       Date:  2017-12-12       Impact factor: 2.584

9.  The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.

Authors:  Rodger Kempsford; Ann Allen; Joanne Bal; David Rubin; Lee Tombs
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

10.  Inhaled β-agonist does not modify sympathetic activity in patients with COPD.

Authors:  Helge Haarmann; Cordula Mohrlang; Uta Tschiesner; David B Rubin; Thore Bornemann; Karin Rüter; Slavtcho Bonev; Tobias Raupach; Gerd Hasenfuß; Stefan Andreas
Journal:  BMC Pulm Med       Date:  2015-04-30       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.